{"id":"W2159334966","doi":"10.1038/sj.bjc.6601856","title":"Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer","year":2004,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":377,"is_retracted":false,"has_abstract":true,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Pharmacokinetics; Doxorubicin; Pharmacology; Toxicity; Medicine; Maximum tolerated dose; Poloxamer; Chemotherapy; Internal medicine; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007982468,0.001050887,0.001953991,0.0004028773,0.0003690054,0.0005619194,0.0004879797,0.0008705021,0.001606631],"category_scores_gemma":[0.0009768393,0.0004077581,0.0005408878,0.0005197726,0.0007487665,0.0005009424,0.000303143,0.002699706,0.0004602921],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008748694,"about_ca_system_score_gemma":0.0009482747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005360298,"about_ca_topic_score_gemma":0.0008585778,"domain_scores_codex":[0.9996579,0.0001562957,0.00001466723,0.00005462898,0.00004233737,0.00007418977],"domain_scores_gemma":[0.9994895,0.00009301669,0.0001146337,0.0000650488,0.0000391954,0.000198549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3180722,0.1237812,0.01348117,0.0006161957,0.0008788425,0.000879538,0.001081051,0.008869885,0.2935517,0.0005867801,0.004880156,0.2333213],"study_design_scores_gemma":[0.1076458,0.8370453,0.02078956,0.00003194906,0.0002955666,0.0009323941,0.0001030796,0.002589453,0.02476369,0.0003130236,0.005449043,0.00004107915],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996496,0.0008446788,0.0006012298,0.0001474344,0.00003340263,0.00083308,0.0002105289,0.00005824311,0.0007754924],"genre_scores_gemma":[0.9934923,0.001023696,0.001991241,0.0002383759,0.00005587002,0.001128429,0.0008075548,0.00002773458,0.001234659],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001953991,"threshold_uncertainty_score":0.006347597,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008120481377496757,"score_gpt":0.304287108893021,"score_spread":0.2961666275155243,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}